Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
P68032
UPID:
ACTC_HUMAN
Alternative names:
Alpha-cardiac actin
Alternative UPACC:
P68032; P04270
Background:
Actin, alpha cardiac muscle 1, also known as Alpha-cardiac actin, is a highly conserved protein pivotal in cell motility and expressed in all eukaryotic cells. Its presence in cardiac muscle cells underscores its essential role in the contractile system.
Therapeutic significance:
Alpha-cardiac actin is implicated in several cardiac disorders, including dilated cardiomyopathy 1R, familial hypertrophic cardiomyopathy 11, and atrial septal defect 5. These associations highlight its potential as a target for therapeutic intervention in heart disease.